05/26/22 5:05 PMNasdaq : AFMD clinical trialAffimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumors Design and rationale of the phase 1/2a study of AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors DesignRHEA-AIneutral
05/26/22 6:30 AMNasdaq : AFMD conferencesAffimed to Present at the 2022 Jefferies Healthcare ConferenceAffimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, willRHEA-AIneutral
05/24/22 6:30 AMNasdaq : AFMD conferencesearningsAffimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2022 results andRHEA-AIneutral
05/24/22 6:30 AMNasdaq : AFMD Affimed Announces Annual General Meeting of ShareholdersAffimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2022 Annual General Meeting of ShareholdersRHEA-AIneutral
05/16/22 8:00 AMNasdaq : AFMD Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural ImmunityCorrelative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapies First preclinical data set on the combination of AFM28 with natural killer cells, both in co-administration or pre-complexed, demonstrates cytotoxic activityRHEA-AIneutral
05/12/22 10:31 AMNasdaq : AFMD conferencesclinical trialAffimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells via antibody-dependent cellular cytotoxicity. AFM28 induces effective lysis of hematological tumor cells even at low-levels of CD123 expression; leukemic cells in patient bone marrow areRHEA-AIneutral
05/06/22 4:02 PMNasdaq : AFMD Affimed Provides Update on ASCO AFM13-104 Oral PresentationAffimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the American Society of Clinical Oncology (ASCO)RHEA-AIneutral
04/27/22 5:20 PMNasdaq : AFMD CORRECTING and REPLACING -- Affimed N.V.In a press release issued earlier today by Affimed N.V. (Nasdaq: AFMD), please note that the headline named an incorrect organization. It should have mentioned the annual meeting of the American Society of Clinical Oncology (ASCO), not the American Association for Cancer Research. The correctedRHEA-AIneutral
04/27/22 4:05 PMNasdaq : AFMD Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Association for Cancer Research (ASCO)A presentation on the phase 1/2 study evaluating cord blood-derived NK cells that are pre-complexed with the innate cell engager AFM13, in patients with CD30-positive lymphomas will be given in an oral abstract session. Three Trial in Progress posters will present background information and theRHEA-AIneutral
04/18/22 11:28 AMNasdaq : AFMD offeringAffimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional SharesAffimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the closing of its previously announced publicRHEA-AIneutral